{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:48:47Z","timestamp":1769604527963,"version":"3.49.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.hoc.2020.02.009","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T08:07:40Z","timestamp":1588666060000},"page":"757-769","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Early Progression of Follicular Lymphoma"],"prefix":"10.1016","volume":"34","author":[{"given":"Jodi J.","family":"Lipof","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M.","family":"Barr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.hoc.2020.02.009_bib1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2020.02.009_bib2","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1200\/JCO.1988.6.5.919","article-title":"Chromosome studies in the non-Hodgkin's lymphomas: the role of the 14;18 translocation","volume":"6","author":"Rowley","year":"1988","journal-title":"J\u00a0Clin Oncol"},{"issue":"4706","key":"10.1016\/j.hoc.2020.02.009_bib3","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1126\/science.3874430","article-title":"Involvement of the bcl-2 gene in human follicular lymphoma","volume":"228","author":"Tsujimoto","year":"1985","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.hoc.2020.02.009_bib4","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1200\/JCO.2001.19.2.420","article-title":"Frequency of the Bcl-2\/IgH rearrangement in normal individuals: implications for the monitoring of disease in patients with follicular lymphoma","volume":"19","author":"Summers","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2020.02.009_bib5","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.leukres.2005.10.001","article-title":"The bcl-2\/IgH rearrangement in a population of 204 healthy individuals: occurrence, age and gender distribution, breakpoints, and detection method validity","volume":"30","author":"Schmitt","year":"2006","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.hoc.2020.02.009_bib6","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","article-title":"Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience","volume":"122","author":"Tan","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2020.02.009_bib7","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.3109\/10428194.2014.885513","article-title":"Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis","volume":"55","author":"Mozessohn","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"31","key":"10.1016\/j.hoc.2020.02.009_bib8","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.19.01073","article-title":"Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study","volume":"37","author":"Bachy","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2020.02.009_bib9","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.2012.42.4101","article-title":"Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016","volume":"31","author":"Press","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"10.1016\/j.hoc.2020.02.009_bib10","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2020.02.009_bib11","first-page":"412","article-title":"Validation of POD24 as a robust early clinical endpoint of poor survival in follicular lymphoma: results from the Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) investigation using individual data from 5,453 patients on 13 clinical trials","volume":"130","author":"Casulo","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2020.02.009_bib12","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood.2019000258","article-title":"Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma","volume":"134","author":"Freeman","year":"2019","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2020.02.009_bib13","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ajh.24492","article-title":"Early event status informs subsequent outcome in newly diagnosed follicular lymphoma","volume":"91","author":"Maurer","year":"2016","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.hoc.2020.02.009_bib14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/jnci\/djw255","article-title":"Recommendations for Clinical Trial Development in Follicular Lymphoma","volume":"109","author":"Maddocks","year":"2017","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.hoc.2020.02.009_bib15","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1182\/blood-2006-02-003921","article-title":"Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells","volume":"108","author":"Irish","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2020.02.009_bib16","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1172\/JCI72415","article-title":"Germinal center reentries of BCL2-overexpressing B cells drive follicular lymphoma progression","volume":"124","author":"Sungalee","year":"2014","journal-title":"J\u00a0Clin Invest"},{"issue":"9","key":"10.1016\/j.hoc.2020.02.009_bib17","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood-2012-09-457283","article-title":"Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma","volume":"121","author":"Green","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2020.02.009_bib18","doi-asserted-by":"crossref","first-page":"E1116","DOI":"10.1073\/pnas.1501199112","article-title":"Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation","volume":"112","author":"Green","year":"2015","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"12","key":"10.1016\/j.hoc.2020.02.009_bib19","doi-asserted-by":"crossref","first-page":"e1002197","DOI":"10.1371\/journal.pmed.1002197","article-title":"Histological transformation and progression in follicular lymphoma: a clonal evolution study","volume":"13","author":"Kridel","year":"2016","journal-title":"PLoS Med"},{"issue":"21","key":"10.1016\/j.hoc.2020.02.009_bib20","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2020.02.009_bib21","first-page":"51","article-title":"Naturally arising Foxp3-expressing CD25+CD4+ regulatory T\u00a0cells in self-tolerance and autoimmune disease","volume":"305","author":"Sakaguchi","year":"2006","journal-title":"Curr Top Microbiol Immunol"},{"issue":"3","key":"10.1016\/j.hoc.2020.02.009_bib22","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1182\/blood-2005-02-0607","article-title":"CD4+ CD25+ regulatory T\u00a0cells control the induction of antigen-specific CD4+ helper T\u00a0cell responses in cancer patients","volume":"106","author":"Nishikawa","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2020.02.009_bib23","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1365-2249.2008.03642.x","article-title":"Depletion of CD4+ CD25+ regulatory T\u00a0cells inhibits local tumour growth in a mouse model of B cell lymphoma","volume":"152","author":"Heier","year":"2008","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.hoc.2020.02.009_bib24","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1182\/blood-2009-07-235598","article-title":"The architectural pattern of FOXP3-positive T\u00a0cells in follicular lymphoma is an independent predictor of survival and histologic transformation","volume":"115","author":"Farinha","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2020.02.009_bib25","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.2008.18.0513","article-title":"High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma","volume":"27","author":"Carreras","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"34","key":"10.1016\/j.hoc.2020.02.009_bib26","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1200\/JCO.18.02365","article-title":"Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration","volume":"37","author":"Tobin","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2020.02.009_bib27","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2020.02.009_bib28","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","volume":"108","author":"Buske","year":"2006","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.hoc.2020.02.009_bib29","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2020.02.009_bib30","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2141.2009.08065.x","article-title":"Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients","volume":"149","author":"Arcaini","year":"2010","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.hoc.2020.02.009_bib31","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.hoc.2020.02.009_bib32","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood.V126.23.333.333","article-title":"A\u00a0clinicogenetic risk model (m7-FLIPI) prospectively identifies one-half of patients with early disease progression of follicular lymphoma after first-line immunochemotherapy","volume":"126","author":"Vindi","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2020.02.009_bib33","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2020.02.009_bib34","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","article-title":"A\u00a0gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts","volume":"19","author":"Huet","year":"2018","journal-title":"Lancet Oncol"},{"issue":"9873","key":"10.1016\/j.hoc.2020.02.009_bib35","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.hoc.2020.02.009_bib36","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/cam4.1918","article-title":"The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials","volume":"8","author":"Lansigan","year":"2019","journal-title":"Cancer Med"},{"issue":"22","key":"10.1016\/j.hoc.2020.02.009_bib37","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"Mossner","year":"2010","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2020.02.009_bib38","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.hoc.2020.02.009_bib39","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1056\/NEJMc1714337","article-title":"Obinutuzumab treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.hoc.2020.02.009_bib40","doi-asserted-by":"crossref","first-page":"e429","DOI":"10.1016\/S2352-3026(19)30089-4","article-title":"Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"issue":"14","key":"10.1016\/j.hoc.2020.02.009_bib41","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"S2","key":"10.1016\/j.hoc.2020.02.009_bib42","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/hon.75_2629","article-title":"Augment phase III study: lenalidomide\/rituximab (R2) improved efficacy over rituximab\/placebo in relapsed\/refractory follicular patients irrespective of POD24 status","volume":"37","author":"Leonard","year":"2019","journal-title":"Hematol Oncol"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2020.02.009_bib43","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1200\/JCO.2017.35.15_suppl.7502","article-title":"Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed\/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (FL)","volume":"35","author":"Andorsky","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2020.02.009_bib44","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2009.25.3641","article-title":"The PI3K pathway as drug target in human cancer","volume":"28","author":"Courtney","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2020.02.009_bib45","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.hoc.2020.02.009_bib46","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1182\/blood-2016-12-757740","article-title":"Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy","volume":"129","author":"Gopal","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2020.02.009_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9030024","article-title":"Class (I) phosphoinositide 3-kinases in the tumor microenvironment","volume":"9","author":"Gyori","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.hoc.2020.02.009_bib48","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-hodgkin lymphoma","volume":"37","author":"Flinn","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2020.02.009_bib49","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","article-title":"Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"issue":"S2","key":"10.1016\/j.hoc.2020.02.009_bib50","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/hon.57_2631","article-title":"Efficacy and safety in high-risk relapsed or refractory indolent follicular lymphoma patients treated with copanlisib","volume":"37","author":"Dreyling","year":"2019","journal-title":"Hematol Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2020.02.009_bib51","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.bbmt.2017.05.021","article-title":"Autologous stem cell transplantation for follicular lymphoma: favorable long-term survival irrespective of pretransplantation rituximab exposure","volume":"23","author":"Jimenez-Ubieto","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.hoc.2020.02.009_bib52","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/bjh.12741","article-title":"Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure","volume":"165","author":"Kothari","year":"2014","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.hoc.2020.02.009_bib53","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.bbmt.2017.12.771","article-title":"Autologous transplantation in follicular lymphoma with early therapy failure: a National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis","volume":"24","author":"Casulo","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.hoc.2020.02.009_bib54","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1002\/cncr.31374","article-title":"Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure","volume":"124","author":"Smith","year":"2018","journal-title":"Cancer"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:14:48Z","timestamp":1760184888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858820300344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0889858820300344"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2020.02.009","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early Progression of Follicular Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2020.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}